- Home
- GSIW vs GTBP Comparison
GSIW vs GTBP Comparison
Compare GSIW & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- GTBP
- Stock Information
- Founded
- GSIW 2016
- GTBP 1965
- Country
- GSIW Hong Kong
- GTBP United States
- Employees
- GSIW N/A
- GTBP N/A
- Industry
- GSIW
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- GTBP Health Care
- Exchange
- GSIW Nasdaq
- GTBP Nasdaq
- Market Cap
- GSIW 8.1M
- GTBP 5.5M
- IPO Year
- GSIW 2023
- GTBP N/A
- Fundamental
- Price
- GSIW $0.14
- GTBP $0.80
- Analyst Decision
- GSIW
- GTBP Strong Buy
- Analyst Count
- GSIW 0
- GTBP 1
- Target Price
- GSIW N/A
- GTBP $11.00
- AVG Volume (30 Days)
- GSIW 16.9M
- GTBP 430.0K
- Earning Date
- GSIW 01-01-0001
- GTBP 11-13-2025
- Dividend Yield
- GSIW N/A
- GTBP N/A
- EPS Growth
- GSIW N/A
- GTBP N/A
- EPS
- GSIW N/A
- GTBP N/A
- Revenue
- GSIW $5,368,221.00
- GTBP N/A
- Revenue This Year
- GSIW N/A
- GTBP N/A
- Revenue Next Year
- GSIW N/A
- GTBP N/A
- P/E Ratio
- GSIW N/A
- GTBP N/A
- Revenue Growth
- GSIW 283.23
- GTBP N/A
- 52 Week Low
- GSIW $0.09
- GTBP $0.63
- 52 Week High
- GSIW $8.35
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- GSIW 40.30
- GTBP 28.85
- Support Level
- GSIW $0.09
- GTBP $0.63
- Resistance Level
- GSIW $0.20
- GTBP $0.95
- Average True Range (ATR)
- GSIW 0.02
- GTBP 0.10
- MACD
- GSIW 0.03
- GTBP 0.02
- Stochastic Oscillator
- GSIW 50.43
- GTBP 30.98
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.